Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MET_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MET_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MET_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MET_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MET_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MET_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MET_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MET_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MET_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19029058 | Lung | IAC | positive regulation of supramolecular fiber organization | 36/2061 | 209/18723 | 4.34e-03 | 3.44e-02 | 36 |
GO:00454466 | Lung | IAC | endothelial cell differentiation | 23/2061 | 118/18723 | 4.53e-03 | 3.59e-02 | 23 |
GO:0010594 | Lung | IAC | regulation of endothelial cell migration | 39/2061 | 232/18723 | 4.73e-03 | 3.68e-02 | 39 |
GO:00435425 | Lung | IAC | endothelial cell migration | 45/2061 | 279/18723 | 5.62e-03 | 4.14e-02 | 45 |
GO:00346148 | Lung | IAC | cellular response to reactive oxygen species | 28/2061 | 155/18723 | 5.72e-03 | 4.18e-02 | 28 |
GO:00311133 | Lung | IAC | regulation of microtubule polymerization | 13/2061 | 55/18723 | 5.78e-03 | 4.21e-02 | 13 |
GO:00465803 | Lung | IAC | negative regulation of Ras protein signal transduction | 12/2061 | 49/18723 | 5.82e-03 | 4.23e-02 | 12 |
GO:000989613 | Lung | AIS | positive regulation of catabolic process | 103/1849 | 492/18723 | 9.59e-14 | 1.86e-10 | 103 |
GO:004348413 | Lung | AIS | regulation of RNA splicing | 45/1849 | 148/18723 | 2.75e-12 | 2.67e-09 | 45 |
GO:003133113 | Lung | AIS | positive regulation of cellular catabolic process | 89/1849 | 427/18723 | 6.12e-12 | 4.46e-09 | 89 |
GO:000701513 | Lung | AIS | actin filament organization | 88/1849 | 442/18723 | 1.02e-10 | 3.13e-08 | 88 |
GO:005105611 | Lung | AIS | regulation of small GTPase mediated signal transduction | 66/1849 | 302/18723 | 4.26e-10 | 9.53e-08 | 66 |
GO:004802413 | Lung | AIS | regulation of mRNA splicing, via spliceosome | 32/1849 | 101/18723 | 1.20e-09 | 2.42e-07 | 32 |
GO:190331112 | Lung | AIS | regulation of mRNA metabolic process | 60/1849 | 288/18723 | 1.74e-08 | 2.47e-06 | 60 |
GO:005068412 | Lung | AIS | regulation of mRNA processing | 36/1849 | 137/18723 | 3.06e-08 | 3.79e-06 | 36 |
GO:000206413 | Lung | AIS | epithelial cell development | 48/1849 | 220/18723 | 1.06e-07 | 1.18e-05 | 48 |
GO:005101713 | Lung | AIS | actin filament bundle assembly | 38/1849 | 157/18723 | 1.36e-07 | 1.44e-05 | 38 |
GO:006157213 | Lung | AIS | actin filament bundle organization | 38/1849 | 161/18723 | 2.71e-07 | 2.37e-05 | 38 |
GO:004308711 | Lung | AIS | regulation of GTPase activity | 65/1849 | 348/18723 | 3.35e-07 | 2.83e-05 | 65 |
GO:003103213 | Lung | AIS | actomyosin structure organization | 43/1849 | 196/18723 | 4.08e-07 | 3.25e-05 | 43 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MET | SNV | Missense_Mutation | | c.1695N>G | p.Ile565Met | p.I565M | P08581 | protein_coding | deleterious(0) | possibly_damaging(0.831) | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
MET | SNV | Missense_Mutation | | c.674G>A | p.Gly225Asp | p.G225D | P08581 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MET | SNV | Missense_Mutation | | c.2975N>C | p.Arg992Thr | p.R992T | P08581 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MET | SNV | Missense_Mutation | | c.1454N>T | p.Pro485Leu | p.P485L | P08581 | protein_coding | tolerated(0.07) | benign(0.059) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MET | SNV | Missense_Mutation | | c.2389G>A | p.Val797Met | p.V797M | P08581 | protein_coding | tolerated(0.06) | possibly_damaging(0.751) | TCGA-AR-A24K-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
MET | SNV | Missense_Mutation | | c.2489N>T | p.Gln830Leu | p.Q830L | P08581 | protein_coding | tolerated(0.17) | benign(0.1) | TCGA-B6-A0RS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
MET | SNV | Missense_Mutation | novel | c.1121N>A | p.Phe374Tyr | p.F374Y | P08581 | protein_coding | tolerated(0.09) | probably_damaging(0.941) | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD |
MET | SNV | Missense_Mutation | | c.1234C>G | p.Arg412Gly | p.R412G | P08581 | protein_coding | tolerated(0.15) | benign(0.007) | TCGA-BH-A0W4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MET | SNV | Missense_Mutation | rs540540827 | c.1240G>A | p.Asp414Asn | p.D414N | P08581 | protein_coding | tolerated(0.21) | possibly_damaging(0.466) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
MET | insertion | Frame_Shift_Ins | novel | c.3287_3288insTT | p.His1097CysfsTer7 | p.H1097Cfs*7 | P08581 | protein_coding | | | TCGA-A8-A0A1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | | CBT-101 | | |
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | inhibitor | 252166505 | TEPOTINIB | |
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | inhibitor | 384403668 | | |
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | | Ficlatuzumab | FICLATUZUMAB | 24901237 |
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | inhibitor | CHEMBL2103851 | AMUVATINIB | |
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | inhibitor | ARQ 197 | | |
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | | ENTRECTINIB | ENTRECTINIB | |
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | | Imatinib | IMATINIB | 28514312 |
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | | TEPOTINIB | TEPOTINIB | 32469185,24061647 |
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | | PALBOCICLIB | PALBOCICLIB | |